This segment focuses on the research and development of novel cancer immunotherapies, specifically targeting the tumor microenvironment. Surface Oncology utilizes its expertise in antibody engineering to develop fully human monoclonal antibodies. Key technologies include the development of antibodies targeting extracellular adenosine (NZV930), CD39 (SRF617), IL-27 (SRF388), CD112R (GSK4381562), and CCR8 (SRF114). Research activities include preclinical studies, clinical trials, and collaborations with partners like GlaxoSmithKline and Vaccinex. The therapeutic areas covered are primarily oncology, with the goal of improving patient outcomes by providing new treatment options for various cancers. Market positioning is based on developing innovative therapies with the potential to address unmet medical needs. Future opportunities include expanding the pipeline and advancing clinical programs. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials. Partnerships with pharmaceutical companies are crucial for advancing research and commercialization.

This segment encompasses the clinical development of Surface Oncology's therapeutic candidates. It involves designing and executing clinical trials to evaluate the safety and efficacy of novel immunotherapies. The primary focus is on advancing antibody-based therapies through various phases of clinical trials, including Phase 1, 2, and potentially 3 trials. The technologies employed include the use of monoclonal antibodies and the assessment of biomarkers to monitor treatment response. Therapeutic areas include various cancers, with the aim of improving patient outcomes through targeted therapies. Patient impact is measured through clinical trial results, including response rates, progression-free survival, and overall survival. Market positioning is based on the development of innovative therapies with the potential to address unmet medical needs in oncology. Future opportunities include expanding the clinical trial portfolio and securing regulatory approvals. Regulatory aspects involve adherence to FDA guidelines and other relevant regulations. Partnerships with pharmaceutical companies and research institutions are essential for conducting clinical trials and accelerating the development of new therapies.